| Not Yet Recruiting | SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma NCT07526792 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 3 |
| Not Yet Recruiting | Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma NCT07460245 | Gruppo Oncologico Italiano di Ricerca Clinica | Phase 2 |
| Recruiting | Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma NCT05321316 | Peking University Cancer Hospital & Institute | N/A |
| Recruiting | A Study of GEN1106 in Participants With Solid Tumors NCT07416123 | Genmab | Phase 1 |
| Recruiting | Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC NCT07322263 | Michael A. O'Donnell | Phase 2 |
| Recruiting | A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer NCT07532902 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothel NCT07421700 | Pfizer | Phase 1 / Phase 2 |
| Recruiting | Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma NCT07492628 | Beijing Biotech | Phase 1 |
| Withdrawn | N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer NCT07217496 | Vadim S Koshkin | Phase 1 |
| Not Yet Recruiting | A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer NCT07386847 | Pfizer | — |
| Recruiting | A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma NCT07390617 | Memorial Sloan Kettering Cancer Center | — |
| Recruiting | Circulating Tumor DNA Response In Urothelial Cancer NCT07183319 | University of Oklahoma | Phase 2 |
| Recruiting | Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy NCT07234968 | Thomas Jefferson University | N/A |
| Recruiting | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and NCT07285044 | Mayo Clinic | Phase 2 |
| Recruiting | Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced NCT07241793 | Sun Yat-sen University | Phase 2 |
| Recruiting | Women With isoLated acUte cyStitis and Macroscopic Hematuria. Is Further Investigation Needed? NCT07037589 | Vastra Gotaland Region | — |
| Recruiting | Compression Stockings to Prevent Peripheral Neuropathy Caused by Antibody-Drug Conjugates in Urothelial Carcin NCT07164950 | Sheng Zhang | N/A |
| Recruiting | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers NCT06966024 | Deciphera Pharmaceuticals, LLC | Phase 1 |
| Recruiting | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ So NCT07169734 | Alentis Therapeutics AG | Phase 1 / Phase 2 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors NCT07090499 | Pfizer | Phase 1 |
| Recruiting | A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer NCT06774131 | UroGen Pharma Ltd. | Phase 3 |
| Recruiting | 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer NCT07314723 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 2 |
| Recruiting | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematolog NCT07118176 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers NCT06967961 | Institut Claudius Regaud | N/A |
| Recruiting | Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer NCT06356155 | University of Michigan Rogel Cancer Center | Phase 2 |
| Recruiting | Trastuzumab in Combination With Serplulimab and Chemotherapy for the Treatment of HER2-overexpressing Unresect NCT07506057 | Xiujuan Qu | Phase 2 |
| Recruiting | Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic U NCT07043972 | Fox Chase Cancer Center | Phase 2 |
| Not Yet Recruiting | Clinical Application of PET Imaging Targeting Nectin-4 in Malignant Tumors NCT06994078 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | N/A |
| Recruiting | Olfactive Detection of Urothelial Carcinoma by Sniffer Dogs NCT07334314 | University Hospital, Strasbourg, France | — |
| Recruiting | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187 | Dren Bio | Phase 1 |
| Not Yet Recruiting | Performance Evaluation of a Urine-based Methylation Assay for Urothelial Carcinoma NCT06912672 | Shanghai Epiprobe Biotechnology Co., Ltd. | — |
| Recruiting | A Study of MT-4561 in Patients With Various Advanced Solid Tumors NCT06943521 | Tanabe Pharma America, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Ur NCT06857175 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 |
| Active Not Recruiting | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab NCT06632951 | AbbVie | Phase 2 |
| Recruiting | 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma NCT06823427 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 2 |
| Recruiting | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors NCT06695845 | Jazz Pharmaceuticals | Phase 2 |
| Recruiting | Ivonescimab in the Treatment of Multiple Advanced Tumors NCT06683846 | Fudan University | Phase 2 |
| Recruiting | Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence NCT06682728 | University of California, Irvine | Phase 2 |
| Recruiting | A Phase 2 Clinical Study of ABSK061 and ABSK043 NCT06632262 | Abbisko Therapeutics Co, Ltd | Phase 2 |
| Recruiting | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors NCT06617169 | Monopar Therapeutics | Phase 1 |
| Active Not Recruiting | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Blad NCT06331299 | UroGen Pharma Ltd. | Phase 3 |
| Recruiting | Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma NCT06318871 | Dana-Farber Cancer Institute | EARLY_Phase 1 |
| Recruiting | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma NCT06582017 | Nammi Therapeutics Inc | Phase 1 |
| Recruiting | 9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial NCT06592326 | Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 3 |
| Withdrawn | Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior NCT06424717 | EMD Serono Research & Development Institute, Inc. | Phase 2 |
| Not Yet Recruiting | Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor NCT06551896 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSIT NCT06396533 | Fox Chase Cancer Center | — |
| Terminated | Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in Fr NCT06421311 | Bristol-Myers Squibb | — |
| Not Yet Recruiting | Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients NCT06469229 | Changhai Hospital | — |
| Not Yet Recruiting | Urine DNA Methylation Detection for Hematuria Evaluation NCT06427993 | Changhai Hospital | — |
| Recruiting | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezo NCT06332755 | LG Chem | Phase 1 |
| Recruiting | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors NCT06337084 | Monopar Therapeutics | Phase 1 |
| Recruiting | A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma NCT06405425 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatmen NCT06451497 | Zumutor Biologics Inc. | Phase 1 |
| Recruiting | Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma NCT06262516 | Case Comprehensive Cancer Center | N/A |
| Active Not Recruiting | JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study NCT06412848 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | — |
| Recruiting | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected NCT06265285 | Mayo Clinic | Phase 2 |
| Recruiting | Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessmen NCT06138561 | Dana-Farber Cancer Institute | — |
| Recruiting | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors NCT06293898 | SystImmune Inc. | Phase 1 |
| Terminated | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors NCT06285097 | Pfizer | Phase 1 |
| Unknown | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors NCT06221774 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 1 / Phase 2 |
| Recruiting | Prospective Validation Study of High Volume Urine DNA Testing in Individuals With Suspicion of Urothelial Canc NCT06310759 | Tampere University Hospital | — |
| Terminated | PRO1107 in Patients With Advanced Solid Tumors NCT06171789 | Genmab | Phase 1 / Phase 2 |
| Recruiting | A Study of Ward Admissions for Haematuria NCT07395037 | British Urology Researchers in Surgical Training | — |
| Recruiting | A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Ca NCT06040762 | University of Washington | N/A |
| Active Not Recruiting | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT NCT06111235 | CG Oncology, Inc. | Phase 3 |
| Recruiting | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma a NCT05965856 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto NCT05874921 | UroGen Pharma Ltd. | — |
| Recruiting | Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria NCT05889195 | Pacific Edge Limited | — |
| Recruiting | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Meta NCT06047379 | Neonc Technologies, Inc. | Phase 1 / Phase 2 |
| Unknown | 18F-LN1 PET/CT in Urothelial Carcinomas NCT06120413 | Sichuan Provincial People's Hospital | — |
| Terminated | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Can NCT06034860 | Molecular Templates, Inc. | Phase 1 |
| Unknown | Immunotherapy in Upper Tract Urothelial Carcinoma NCT06113367 | Assistance Publique - Hôpitaux de Paris | — |
| Withdrawn | Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial NCT05894447 | Weill Medical College of Cornell University | Phase 1 |
| Withdrawn | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer N NCT05564416 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER) NCT06101290 | University of California, Davis | N/A |
| Active Not Recruiting | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 NCT05911295 | Seagen, a wholly owned subsidiary of Pfizer | Phase 3 |
| Recruiting | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors W NCT06022757 | Evopoint Biosciences Inc. | Phase 1 / Phase 2 |
| Terminated | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies NCT05861947 | Aurigene Discovery Technologies Limited | Phase 1 |
| Active Not Recruiting | Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC NCT05768347 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Unknown | A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Me NCT06178601 | Shanxi Province Cancer Hospital | Phase 2 |
| Completed | Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER NCT05945108 | AstraZeneca | — |
| Not Yet Recruiting | Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation NCT05912205 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Completed | HER2 and LA/mUC: A Multi-country Chart Review Cohort Study NCT05902494 | Seagen, a wholly owned subsidiary of Pfizer | — |
| Active Not Recruiting | Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma NCT05923190 | Fox Chase Cancer Center | Phase 2 |
| Active Not Recruiting | A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimbereli NCT05335941 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors NCT05867303 | RemeGen Co., Ltd. | Phase 1 |
| Recruiting | A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract NCT05868265 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | UroCAD for Hematuria Evaluation--A Prospective, Multi-center Study NCT05893316 | Changhai Hospital | — |
| Completed | Research on the Accurate Diagnosis of Urinary Tract Tumors and the Development of Kits NCT06193941 | Zhongnan Hospital | — |
| Unknown | The Efficacy of the IUrisure for Detection of Recurrent Urothelial Carcinoma NCT06564363 | Wuhan Ammunition Life-tech Co., Ltd | — |
| Withdrawn | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer NCT05496192 | Bristol-Myers Squibb | Phase 2 |
| Recruiting | Safely Reduce Cystoscopic Evaluations for Hematuria Patients NCT06026189 | Erasmus Medical Center | N/A |
| Withdrawn | Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy NCT05574504 | AdventHealth | Phase 2 |
| Recruiting | Bladder Cancer Screening Trial NCT05646485 | University of Texas Southwestern Medical Center | N/A |
| Unknown | Safety and Efficacy Study of QLF31907 in Advanced Melanoma and Urothelial Carcinoma NCT05823246 | Qilu Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study) NCT06218433 | Tampere University Hospital | N/A |
| Terminated | A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder NCT05699135 | Pfizer | — |
| Terminated | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours NCT05714553 | NuCana plc | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combi NCT05661955 | BeiGene | Phase 1 / Phase 2 |
| Completed | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizum NCT05585034 | Xencor, Inc. | Phase 1 |
| Recruiting | Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer NCT05600127 | Erasmus Medical Center | Phase 2 |
| Active Not Recruiting | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors NCT05544552 | Tyra Biosciences, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced NCT05562830 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Completed | A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07) NCT05524545 | ALX Oncology Inc. | Phase 1 |
| Recruiting | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combinat NCT05581004 | Genentech, Inc. | Phase 1 |
| Active Not Recruiting | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer NCT05620134 | Salubris Biotherapeutics Inc | Phase 1 / Phase 2 |
| Unknown | A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC NCT05775874 | Abbisko Therapeutics Co, Ltd | Phase 2 |
| Unknown | Study of Disitamab Vedotin Combined With Gemcitabine in Neoadjuvant Treatment of Urothelial Carcinoma NCT05723991 | Chunguang yang (101937) | Phase 4 |
| Completed | PSMA Expression and PSMA PET Imaging in Soft Tissue Sarcomas and Urothelial Cell Carcinomas NCT05522257 | Leiden University Medical Center | N/A |
| Recruiting | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease NCT05229614 | CNAO National Center of Oncological Hadrontherapy | Phase 2 |
| Completed | A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has S NCT05431777 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | — |
| Active Not Recruiting | Pembrolizumab in Muscle-invasive Bladder Cancer NCT05406713 | Matthew Galsky | Phase 2 |
| Unknown | Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies. NCT06321640 | European Institute of Oncology | — |
| Recruiting | A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma NCT05302284 | RemeGen Co., Ltd. | Phase 3 |
| Recruiting | Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer NCT05239624 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Recruiting | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 NCT04879329 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Unknown | Urothelial Tumor Risk Genes Detection With Genetron Uro V1 and LC-WGS NCT04994197 | Ruijin Hospital | — |
| Terminated | A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alteratio NCT05242822 | Kinnate Biopharma | Phase 1 |
| Completed | Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer NCT05226117 | IRCCS San Raffaele | Phase 2 |
| Active Not Recruiting | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC NCT05200988 | The Netherlands Cancer Institute | Phase 2 |
| Recruiting | A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China NCT05337189 | Creative Biosciences (Guangzhou) Co., Ltd. | — |
| Recruiting | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in NCT05078047 | UNICANCER | Phase 3 |
| Withdrawn | Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma NCT05107427 | 4D pharma plc | Phase 2 |
| Active Not Recruiting | A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder NCT05243550 | UroGen Pharma Ltd. | Phase 3 |
| Withdrawn | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select NCT05234606 | Silverback Therapeutics | Phase 1 / Phase 2 |
| Recruiting | ARON-2 Study-Multicentric International Retrospective Study NCT05290038 | Matteo Santoni | — |
| Terminated | An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoa NCT04586244 | Incyte Corporation | Phase 2 |
| Terminated | RTX-224 Monotherapy in Patients With Solid Tumors NCT05219578 | Rubius Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC NCT06120374 | Peking University First Hospital | — |
| Completed | Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer NCT05136898 | UroGen Pharma Ltd. | Phase 3 |
| Terminated | Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib NCT05052372 | xCures | — |
| Recruiting | Bio Clinical Collection of Urothelial Carcinoma NCT04970472 | University Hospital, Toulouse | — |
| Active Not Recruiting | A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With NCT05137262 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma NCT05030077 | Tianjin Medical University Second Hospital | Phase 2 |
| Recruiting | Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urina NCT04617756 | Centre Hospitalier Universitaire de Nīmes | Phase 2 |
| Unknown | UroCAD Assay Combined With Computed Tomography Urography and Urine Cytology for UTUC Diagnosis. NCT05043662 | Changhai Hospital | — |
| Completed | Pre-operative Immunotherapy in Stage II-III Urothelial Cancer NCT04871594 | The Netherlands Cancer Institute | Phase 1 |
| Recruiting | GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453 | GI Innovation, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours NCT04969835 | Avacta Life Sciences Ltd | Phase 1 |
| Completed | A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA NCT04822350 | Pfizer | — |
| Completed | Value of Cortactin Expression in Invasive and Non-invasive Urinary Bladder Urothelial Carcinoma in Egyptian Po NCT05070039 | Sohag University | N/A |
| Terminated | Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy T NCT04887831 | G1 Therapeutics, Inc. | Phase 2 |
| Unknown | A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 NCT05086666 | Abbisko Therapeutics Co, Ltd | Phase 1 / Phase 2 |
| Recruiting | TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelia NCT04678362 | Centre Francois Baclesse | Phase 2 |
| Recruiting | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advan NCT04895709 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Completed | Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Pati NCT05046665 | South Metropolitan Health Service | Phase 1 |
| Active Not Recruiting | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors NCT04902872 | Cybrexa Therapeutics | Phase 1 / Phase 2 |
| Recruiting | Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiothe NCT04892849 | University of Erlangen-Nürnberg Medical School | — |
| Unknown | A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors NCT04773951 | Shanghai Junshi Bioscience Co., Ltd. | Phase 1 |
| Active Not Recruiting | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Express NCT04802876 | SOLTI Breast Cancer Research Group | Phase 2 |
| Terminated | Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle- NCT04579133 | Latin American Cooperative Oncology Group | Phase 2 |
| Terminated | A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer NCT04688931 | UroGen Pharma Ltd. | Phase 3 |
| Unknown | A Study of ICP-192 in Patients With Advanced Solid Tumors NCT04565275 | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Multimodal Spectroscopy to Detect Urothelial Cancer in Urine NCT04718948 | University of Florence | — |
| Completed | Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder NCT04553939 | Henan Cancer Hospital | Phase 2 |
| Terminated | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors NCT04628780 | Pfizer | Phase 1 |
| Completed | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metast NCT04666688 | PureTech | Phase 1 / Phase 2 |
| Completed | Evolution of Proteomic Profiles of Intestinal Microbiota in Patients With Locally Advanced or Metastatic Uroth NCT04566029 | Centre Hospitalier Universitaire de Nīmes | — |
| Unknown | Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic NCT04770974 | University of Florence | — |
| Unknown | A Study on Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Urothelial Car NCT04211012 | Jun Guo | Phase 2 |
| Terminated | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy NCT04596033 | Genocea Biosciences, Inc. | Phase 1 |
| Completed | GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have P NCT04601402 | Genome & Company | Phase 1 |
| Recruiting | Liquid Biospy for Urinary Cancers NCT06116396 | IRCCS San Raffaele | — |
| Terminated | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic NCT04260802 | Ocellaris Pharma, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and NCT04452214 | Cantargia AB | Phase 1 |
| Active Not Recruiting | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NCT04140526 | OncoC4, Inc. | Phase 1 / Phase 2 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid NCT04242199 | Incyte Corporation | Phase 1 |
| Active Not Recruiting | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers NCT04459273 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Terminated | Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma NCT04341740 | University of Oklahoma | N/A |
| Unknown | Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma NCT04730219 | Tianjin Medical University Second Hospital | Phase 2 |
| Completed | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies NCT04383938 | Aprea Therapeutics | Phase 1 / Phase 2 |
| Completed | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid NCT04344795 | Tempest Therapeutics | Phase 1 |
| Unknown | Vasculogenic Mimicry in Urothelial Carcinoma NCT04295967 | Assiut University | — |
| Withdrawn | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention NCT03517995 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Terminated | Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma NCT04322643 | Case Comprehensive Cancer Center | Phase 2 |
| Unknown | Exercise-based Pre-habilitation in Bladder Cancer Patients Prior to Radical Cystectomy: a Feasibility Study NCT04223063 | Ross Mason | N/A |
| Active Not Recruiting | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (K NCT04152499 | Klus Pharma Inc. | Phase 1 / Phase 2 |
| Active Not Recruiting | 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy NCT04018053 | Brigham and Women's Hospital | EARLY_Phase 1 |
| Unknown | Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response NCT04146064 | University Health Network, Toronto | — |
| Active Not Recruiting | Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma NCT04004442 | University of Oklahoma | Phase 1 |
| Unknown | A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects NCT04264936 | Peking University Cancer Hospital & Institute | Phase 1 / Phase 2 |
| Terminated | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies NCT04244552 | Atreca, Inc. | Phase 1 |
| Completed | Biological Effect of Vitamin D in Patients With Urothelial Carcinoma NCT04197089 | Germans Trias i Pujol Hospital | Phase 4 |
| Terminated | Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. NCT04066595 | Johannes Gutenberg University Mainz | Phase 2 |
| Recruiting | A Multicenter Cancer Biospecimen Collection Study NCT04510129 | Cofactor Genomics, Inc. | — |
| Terminated | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesotheli NCT04173338 | Augusta University | Phase 1 |
| Unknown | A Prospective, Multi-centre, Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-up NCT04432909 | Changhai Hospital | — |
| Terminated | LITT and Pembrolizumab in Recurrent Brain Metastasis NCT04187872 | University of Florida | Phase 1 |
| Completed | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Adva NCT04200963 | Ikena Oncology | Phase 1 |
| Active Not Recruiting | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanc NCT04198766 | Inhibrx Biosciences, Inc | Phase 1 / Phase 2 |
| Terminated | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors NCT04116320 | Craig L Slingluff, Jr | Phase 1 |
| Unknown | Efficacy and Utility of Cxbladder Tests in Hematuria Patients NCT04943380 | Pacific Edge Limited | — |
| Completed | Fear of Cancer Recurrence in Genitourinary Cancer NCT04535921 | Ludwig-Maximilians - University of Munich | — |
| Recruiting | An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Bi NCT04623502 | University of Texas Southwestern Medical Center | N/A |
| Terminated | KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer NCT03915405 | Kyowa Kirin, Inc. | Phase 1 |
| Completed | Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Uroth NCT03980041 | Infinity Pharmaceuticals, Inc. | Phase 2 |
| Completed | Prospective Trial for Examining Hematuria Using Computed Tomography NCT04077359 | Oslo University Hospital | N/A |
| Completed | STRATA: Safe Testing of Risk for AsymptomaTic MicrohematuriA NCT03988309 | Pacific Edge Limited | N/A |
| Completed | Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemother NCT03945084 | University of Turin, Italy | Phase 2 |
| Completed | A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer NCT04073602 | RemeGen Co., Ltd. | Phase 2 |
| Terminated | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumo NCT04060342 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | Phase 1 |
| Completed | A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer NCT03735680 | OncoNano Medicine, Inc. | Phase 2 |
| Completed | Derazantinib and Atezolizumab in Patients With Urothelial Cancer NCT04045613 | Basilea Pharmaceutica | Phase 1 / Phase 2 |
| Completed | Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carc NCT04314245 | AnchorDx Medical Co., Ltd. | — |
| Terminated | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor ( NCT03992131 | pharmaand GmbH | Phase 1 / Phase 2 |
| Terminated | Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular I NCT04106167 | Fate Therapeutics | — |
| Active Not Recruiting | Diagnostic Values of Urothelial Carcinomas: Single-bolus Versus Split-bolus Computed Tomography Urography NCT04113603 | Chang Gung Memorial Hospital | N/A |
| Completed | Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patien NCT03869190 | Hoffmann-La Roche | Phase 1 / Phase 2 |
| Completed | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tum NCT03849469 | Xencor, Inc. | Phase 1 |
| Active Not Recruiting | Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Ur NCT03967977 | BeiGene | Phase 3 |
| Completed | Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin- NCT03898180 | Merck Sharp & Dohme LLC | Phase 3 |
| Unknown | Application of UCAD for Diagnosing Urothelial Carcinoma. NCT03998371 | Changhai Hospital | — |
| Unknown | Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma NCT04047693 | Pusan National University Yangsan Hospital | Phase 2 |
| Completed | Improve Checkpoint-blockade Response in Advanced Urothelial Cancer NCT03871036 | The Netherlands Cancer Institute | Phase 1 / Phase 2 |
| Completed | A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) NCT03752398 | Xencor, Inc. | Phase 1 |
| Completed | Evaluation of NanoDoce® in Participants With Urothelial Carcinoma NCT03636256 | NanOlogy, LLC | Phase 1 / Phase 2 |
| Unknown | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients NCT03924466 | Universitair Ziekenhuis Brussel | Phase 2 |
| Completed | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas NCT03894618 | Shattuck Labs, Inc. | Phase 1 |
| Completed | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers NCT03829436 | Tempest Therapeutics | Phase 1 |
| Completed | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumo NCT03841110 | Fate Therapeutics | Phase 1 |
| Completed | A Study of a Personalized Neoantigen Cancer Vaccine NCT03639714 | Gritstone bio, Inc. | Phase 1 / Phase 2 |
| Completed | IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors NCT03758781 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Active Not Recruiting | A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated NCT03782207 | Hoffmann-La Roche | — |
| Unknown | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors NCT03827837 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Completed | Patient-reported Outcomes in Bladder Cancer NCT03584659 | Rigshospitalet, Denmark | N/A |
| Completed | Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma NCT03788746 | AstraZeneca | — |
| Terminated | Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma NCT03486197 | University of Washington | Phase 2 |
| Active Not Recruiting | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small NCT03582475 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subje NCT03809013 | RemeGen Co., Ltd. | Phase 2 |
| Terminated | Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients Wi NCT03737123 | Nabil Adra | Phase 2 |
| Completed | Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors NCT03689192 | Herlev Hospital | Phase 1 |
| Active Not Recruiting | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Im NCT03228667 | ImmunityBio, Inc. | Phase 2 |
| Completed | Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma NCT03658304 | University of Florida | Phase 2 |
| Completed | Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer NCT03557918 | Matthew Galsky | Phase 2 |
| Completed | A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer NCT03575013 | Yousef Zakharia | Phase 1 |
| Completed | A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer NCT03558503 | UroGen Pharma Ltd. | Phase 2 |
| Unknown | A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma NCT03676946 | Lee's Pharmaceutical Limited | Phase 1 / Phase 2 |
| Completed | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors NCT03665285 | NextCure, Inc. | Phase 1 / Phase 2 |
| Completed | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies NCT03652077 | Incyte Corporation | Phase 1 |
| Terminated | A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Adv NCT03606174 | Mirati Therapeutics Inc. | Phase 2 |
| Completed | Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases NCT03520231 | University Health Network, Toronto | Phase 2 |
| Completed | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine NCT03633110 | Genocea Biosciences, Inc. | Phase 1 / Phase 2 |
| Completed | Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer NCT03523572 | Daiichi Sankyo | Phase 1 |
| Unknown | The Efficacy of Neoadjuvant Atezolizumab Treatment in Patients With Advanced Urothelial Bladder Cancer NCT03577132 | Seoul National University Hospital | N/A |
| Completed | A Study of Personalized Neoantigen Cancer Vaccines NCT03794128 | Gritstone bio, Inc. | — |
| Completed | Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectom NCT03171493 | Vyriad, Inc. | Phase 1 |
| Completed | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors NCT03517488 | Xencor, Inc. | Phase 1 |
| Active Not Recruiting | Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue NCT06339138 | Mayo Clinic | — |
| Terminated | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies NCT03407976 | University of Utah | Phase 1 |
| Completed | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies NCT03538028 | Incyte Biosciences International Sàrl | Phase 1 |
| Terminated | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma NCT03397394 | pharmaand GmbH | Phase 2 |
| Completed | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent NCT03502785 | Inovio Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma NCT03473756 | Bayer | Phase 1 |
| Unknown | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors NCT03475953 | Institut Bergonié | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer NCT03473743 | Janssen Research & Development, LLC | Phase 1 / Phase 2 |
| Terminated | A Study of ADXS-NEO Expressing Personalized Tumor Antigens NCT03265080 | Advaxis, Inc. | Phase 1 |
| Completed | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors NCT03511391 | University Hospital, Ghent | Phase 2 |
| Unknown | The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence NCT03062059 | National Cancer Center, Korea | Phase 2 |
| Completed | A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentin NCT03330886 | Hoffmann-La Roche | — |
| Completed | Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer NCT03240016 | University of Michigan Rogel Cancer Center | Phase 2 |
| Terminated | Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma NCT03287050 | University of Michigan Rogel Cancer Center | Phase 2 |
| Completed | Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy NCT03387761 | The Netherlands Cancer Institute | Phase 1 |
| Recruiting | SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry NCT03452774 | Massive Bio, Inc. | — |
| Terminated | A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metas NCT03399643 | Hoffmann-La Roche | — |
| Completed | A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer NCT03507166 | RemeGen Co., Ltd. | Phase 2 |
| Completed | Investigation and Detection of Urological Neoplasia in Patients Referred With Suspected Urinary Tract Cancer: NCT03548688 | British Urology Researchers in Surgical Training | — |
| Terminated | A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Ad NCT03311334 | Sumitomo Pharma America, Inc. | Phase 1 / Phase 2 |
| Recruiting | Registry Platform Urologic Cancer NCT03374267 | iOMEDICO AG | — |
| Withdrawn | QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who NCT03197571 | ImmunityBio, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) NCT03232593 | Hoffmann-La Roche | — |
| Recruiting | Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma NCT03291028 | Fox Chase Cancer Center | — |
| Unknown | Development of Diagnostics and Treatment of Urological Cancers NCT02994758 | Helsinki University Central Hospital | N/A |
| Active Not Recruiting | Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinom NCT03179943 | Fox Chase Cancer Center | Phase 2 |
| Recruiting | Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial NCT03317158 | Noah Hahn, M.D. | Phase 1 / Phase 2 |
| Terminated | Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Pr NCT03208712 | University of Michigan Rogel Cancer Center | EARLY_Phase 1 |
| Active Not Recruiting | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers NCT03212404 | Checkpoint Therapeutics, Inc. | Phase 1 |
| Terminated | Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer NCT03272217 | Arjun Balar, MD | Phase 2 |
| Active Not Recruiting | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastati NCT03170960 | Exelixis | Phase 1 |
| Completed | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers NCT03190174 | Sarcoma Oncology Research Center, LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors NCT03252938 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 1 |
| Completed | UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch NCT02643043 | Matthew Milowsky, MD | N/A |
| Unknown | The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence NCT03209206 | Seoul National University Hospital | Phase 2 |
| Completed | SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma NCT02986867 | University of Texas Southwestern Medical Center | N/A |
| Active Not Recruiting | Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With NCT02845323 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Terminated | A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated NCT03029832 | Genentech, Inc. | Phase 2 |
| Completed | Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma NCT02788201 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Tr NCT03093922 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | A Study Evaluating MM-310 in Patients With Solid Tumors NCT03076372 | Merrimack Pharmaceuticals | Phase 1 |
| Completed | Water Versus Saline as Irrigation Fluid for Ureteroscopy NCT03794102 | Emory University | N/A |
| Terminated | Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced NCT02887248 | SCRI Development Innovations, LLC | Phase 2 |
| Withdrawn | A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies NCT02232646 | Sumitomo Pharma America, Inc. | Phase 2 |
| Active Not Recruiting | A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Blad NCT02989584 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer T NCT02983045 | Nektar Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors NCT02717156 | University of Southern California | Phase 2 |
| Active Not Recruiting | Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder NCT02968732 | Fox Chase Cancer Center | N/A |
| Terminated | Glycosylation of Exosomes in Prostate and Urothelial Carcinoma NCT04960956 | Indiana University | — |
| Completed | MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers NCT02989064 | Adaptimmune | Phase 1 |
| Completed | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alte NCT02795156 | SCRI Development Innovations, LLC | Phase 2 |
| Completed | Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy NCT03039413 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | EARLY_Phase 1 |